News
AZ to transfer certain drug rights to Covis Pharma for $270m
AstraZeneca has announced it will transfer global rights to Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group in a $270m deal.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca has announced it will transfer global rights to Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group in a $270m deal.